NewAmsterdam Pharma Co N.V. (NAMS) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$147.78M | +6.8% |
| 2024 | -$158.56M | -12.3% |
| 2023 | -$141.22M | -1424.1% |
| 2022 | $10.66M | +136.1% |
| 2021 | -$29.51M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$147.78M | +6.8% |
| 2024 | -$158.56M | -12.3% |
| 2023 | -$141.22M | -1424.1% |
| 2022 | $10.66M | +136.1% |
| 2021 | -$29.51M | — |